Keywords
lymphoblastic
ALL
palliative care
Oncovin
Prednisone
survival
How to Cite
Abstract
Introduction :
Acute lymphoblastic leukemias (ALL) are malignant hemopathies. It is the most common cancer in children under 15 years old. The objective was to evaluate the OP protocol (Oncovin and Prednisone) in the palliative management of ALL. Patients and Methods: this is a retrospective, descriptive study with an evaluative aim, going from January 2014 to August 2018. This study concerned all the patients followed in the Clinical Hematology Department of the Yopougon University Hospital (Abidjan) for ALL under palliative treatment.
Results :
The mean age of the patients was 33.9 ± 20.25 years (range: 2-76 years). There was a male predominance with a sex ratio of 1.29. The mean time to consultation was 73.2 ± 49.05 days (range: 7-180 days). Hyperleukocytosis was the main reason for consultation (84.6%) with deterioration in general condition (WHO performance status3 in 46.2% cases). There was a predominance of anemic syndrome (94.8%) and severe thrombocytopenia between 0 and 25G / l was observed in 41.0% of cases. The myelogram showed a predominance of cytological type LAL2 in 51.3%. The majority of our patients were predicted to be High risk in 82.1%. The mean survival of patients on palliative OP treatment was 94 days, significant compared to the mean survival without palliative OP treatment which was 20 days.
Conclusion :
The palliative approach using the vincristine-prednisone (OP) protocol improves average survival. This palliative care of patients in advanced or terminal phase of leukemia, which still remains to be studied, can be used in our settings with limited resources.
References
1. Rabian F, Boissel N. LAL chez l’adulte: apport et limite de la prise en charge pédiatrique. Bull Cancer (Paris). 2021;108(2):187‑97.
2. Lara D, Gauthier M. Leucémies aiguës lymphoblastiques. Hématologie. 2014;20(2):116‑29.
3. Farnault L, Boudjarane J, Baccini V E. Leucémies aiguës lymphoblastiques de l’adulte. EM-Consulte. 2014; [13-018-G-40] - Doi : 10.1016/S1155-1984(14)62406-7.
4. Aldoss I, Stein AS. Advances in adult acute lymphoblastic leukemia therapy. Leuk Lymphoma. mai 2018;59(5):1033‑50.
5. Gregory S. Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates. Semin Oncol Nurs. 2019; 35(6):150951.
6. Thomas X, Tavernier E, Le Q-H. Leucémie aiguë lymphoblastique du sujet âgé: pronostic et traitement. Bull Cancer (Paris). 2004;91(9):713‑20.
7. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
8. Koffi KG, Kueviakoe I, Nacoulma E, Sangare A, Sanogo I, Tchetcha B, et al. Aspects epidemiologiques des leucemies aiguës en Cote d’Ivoire. Carcinol Prat En Afr. 2000;3(1):14‑5.
9. Nirina MH, Rakotoarivelo ZL, Ntoezara A, Rasolonjatovo AS, RakotoAlson AO, Rasamindrakotroka A. Épidémiologie et diagnostic des leucémies aiguës à l’hôpital Ravoahangy Andrianavalona Antananarivo Madagascar. J Afr CancerAfrican J Cancer. 2015;7(4):186‑9.
10. Ducassou S. Traitement des leucémies aiguës de l’enfant: aujourd’hui et demain. Perfect En Pédiatrie. 2018; 1(3):185‑91.
11. Richard-Carpentier G, Kantarjian H, Jabbour E. Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. avr 2019;14(2):106‑18. 001 (2) :65-71
12. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 1 nov 2020;105(11):2524‑39.
13. Sawadogo D, Yapo A, Sangaré M, Tolo A, Yayo-Ayé M. Caractéristiques épidémiologiques des patients atteints d’hémopathies malignes à Abidjan au cours de la décennie 1995–2004. J Afr CancerAfrican J Cancer. 2009;1(1):4‑10.
14. Douamba S, Diallo F, Nagalo K, Tamini L, Dao L, Yé D. Les leucémies aiguës lymphoblastiques de l’enfant à Ouagadougou (Burkina Faso): résultats de la prise en charge selon le protocole du Groupe Franco-Africain d’Oncologie Pédiatrique 2005. Pan Afr Med J. 2018; 29(1):1‑5.
15. Saygin C, Grieselhuber N, Blachly J, Byrd JC, Vasu S, Larkin K, et al. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Phacute lymphoblastic leukemia. Leuk Res. 2020; 89:106297.
16. Haque S, Vaiselbuh SR. Vincristine and prednisone regulates cellular and exosomal miR-181a expression differently within the first time diagnosed and the relapsed leukemia B cells. Leuk Res Rep. 2020; 14:100221.
17. Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol OncolJ Hematol Oncol. 2020; 13(1):70.
18. Ganesan P, Kayal S. How I Treat Adult Acute Lymphoblastic Leukemia in India. Indian J Med Paediatr Oncol. 2021, DOI https://doi.org/10.1055/s-0041-1731979.
19. Cook LB, Phillips AA. How I treat adult Tcell leukemia/lymphoma. Blood. 2021; 137 (4): 459‑70.
20. Reid JH, Perissinotti AJ, Benitez LL, Boyer D, Lee W, Burke PW, et al. Hybrid chemotherapy regimen (FLAG-IDAvincristine-prednisone) for acute leukemia with mixed-phenotype blasts. Leuk Res. 2021; 103:106539.
21. Togo B, Traoré F, Leverger G, Diakite A, Diallo S. Leucémie aiguë lymphoblastique de l’enfant: 12 observations au Mali. Médecine Trop. 2011;71(6):629‑31.
22. Nikièma M, Traoré W, Koulidiati J, Kaboré D, Sanou F, Ouattara A et al. Contribution du myélogramme au diagnostic des hémopathies au centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou: à propos de 175 ponctions medullaires. Rev Afr Malgache Rech Sci Santé. 2020;2(1): 17-24.
23. Okello CD, Niyonzima N, Ferraresso M, Kadhumbula S, Ddungu H, Tarlock K, et al. Haematological malignancies in subSaharan Africa: east Africa as an example for improving care. Lancet Haematol. 2021; (10):e756-e769.
24. Ngolet LO, Galiba Atipo Tsiba FO, Malanda F, Nguelongo Ova J, Ibara G, Elira Dokekias 001 (2) :65-71 A. Hémopathies malignes à Brazzaville (Congo): analyse de situation. Médecine Afr Noire. 2018;65(1):37‑43.
25. Andrianarivony RT, Inzaki A, Rakotomahefa Narison ML, Rasolofo J,Rakoto Alson O, et al. Pronostic des leucémies aiguës lymphoblastiques de l’enfant traitées dans le protocole LAL GFAOP 2005. Rev. Malg. Ped. 2018;1(2):39-44.
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 M Maman Brah, M Chefou, A Almoustapha, A Garba, B Kouakou, B Malam-abdou, I Kamara, R Botti, N Danho, A Tolo-diebkilé, I Sanogo